Avantis U.S. Large Cap Value ETF (ARCA: AVLV)

Latest news for Avantis U.S. Large Cap Value ETF (ARCA:AVLV)

Industrials

Consumer Cyclical

Financial Services

Energy

Technology

Consumer Defensive

Basic Materials

Communication Services

Healthcare

Other

Utilities

The fund invests primarily in a diverse group of U.S. companies across market sectors and industry groups. The fund seeks securities of companies that it expects to have higher returns by placing an enhanced emphasis on securities of companies it defines as high profitability or value companies. Conversely, the fund seeks to underweight or exclude securities it expects to have lower returns, such as securities of companies with lower levels of profitability and higher prices relative to their book values or other financial metrics. To identify high profitability or value companies, the portfolio managers may use reported and estimated company financials and market data including, but not limited to, shares outstanding, book value and its components, cash flows, revenue, expenses, accruals and income. Value companies may be defined as those with lower price relative to book value ratio or other fundamental value. High profitability companies may be defined as those with higher cash based operating profitability. The portfolio managers may also consider other factors when selecting a security including industry classification, the past performance of the security relative to other securities, its liquidity, its float, and tax, governance or cost considerations, among others. Under normal market conditions, the fund will invest at least 80% of its assets in equity securities of large capitalization U.S. companies. To determine whether a company is a U.S. company, the portfolio managers will consider various factors, including where the company is headquartered, where the companys principal operations are located, where a majority of the companys revenues are derived, where the principal trading market is located, the country in which the company was legally organized, and whether the company is in the funds benchmark the Russell 1000 Value Index. The fund defines large capitalization companies as those with market capitalizations at least as large as the smallest company in the Russell 1000 Value Index. Though market capitalizations will change from time to time, as of July 31, 2021, the market capitalization of the smallest company in the Russell 1000 Value Index was approximately $786.7 million.

Apple Inc

Meta Platforms, Inc.

Jpmorgan Chase & Co.

Exxon Mobil Corp.

Johnson & Johnson, Inc.

Walmart, Inc.

Amazon.Com Inc

Caterpillar, Inc.

Chevron Corp.

Avantis US Large Cap Value ETF

Avantis U.S. Large Cap Value ETF

Earnings

News

Guidance

Health Care

General

INSP

Inspire Medical Systems Expects FY25 Sales Of $940M-$955M Versus Consensus Of $950.62M

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Crinetics Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNX#NASDAQ">CRNX</a>) with a Buy and maintains $81 price target.

Price Target

Reiteration

Analyst Ratings

CRNX

HC Wainwright & Co. Reiterates Buy on Crinetics Pharmaceuticals, Maintains $81 Price Target

Preliminary, Unaudited Fourth Quarter and Full Year 2024 Revenue and Recent Business Highlights
<ul>
<li>Revenue for the fourth quarter of 2024 is anticipated to be in the range of $239.5 million to $239.7&nbsp;million, an approximately 25% increase over the same quarter of 2023</li>
<li>Revenue for full year 2024 is anticipated to be in the range of $802.6 million to $802.8&nbsp;million, an approximately 28% increase over full year 2023</li>
<li>Activated 72 new centers in the U.S. in the fourth quarter of 2024, bringing the total to 1,435 U.S. medical centers implanting Inspire therapy</li>
<li>Created 12 new sales territories in the U.S. in the fourth quarter of 2024, bringing the total to 335 U.S. sales territories</li>
<li>Initiated the soft launch of the Inspire V neurostimulator with over 40 implants completed in Singapore and the U.S.</li>
<li>Implemented a new organizational structure intended to drive continued growth</li>
</ul>

Inspire Medical Systems Reports Preliminary Q4 And FY2024 Revenues Of $239.5M-$239.7M And $802.6M-$802.8M Versus Consensus Of 233.29M And $796.09M, Respectively

Preliminary Fourth Quarter and Full Year 2024 Financial Results
Based on preliminary, unaudited results, ANI expects Purified Cortrophin Gel net revenues of $59.2 million to $59.8 million for the fourth quarter of 2024 and $197.8 million to $198.4 million for the full year 2024. In addition, the company expects combined ILUVIEN and YUTIQ net revenues of $26.6 million to $27.2 million for the fourth quarter of 2024 and $30.4 million to $31.0 million for the post-acquisition period from September 16, 2024 to December 31, 2024.
Additionally, the Company expects full year 2024 total net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS to be at or above the guidance ranges provided on November 8, 2024.
The information presented above is unaudited and reflects preliminary estimates subject to the completion of financial closing procedures and any adjustments that may result from the finalization of the quarterly and annual review of the Company's consolidated financial statements. ANI will report its full year 2024 results during its fourth quarter 2024 earnings conference call in late February.
Preliminary Full Year 2025 Outlook
For full year 2025, ANI expects total net revenues of between $739 million and $759 million, representing growth of 24% to 27% as compared to the midpoint of 2024 guidance, and adjusted non-GAAP EBITDA of between $182 million and $192 million.
ANI will provide its full 2025 financial guidance during its fourth quarter 2024 earnings conference call in late February.

ANIP

ANI Pharma Expects Q4 Purified Cortrophin Gel Revenues of $59.2M-$59.8M And $197.8M-$198.4M For FY24, Q4 ILUVIEN And YUTIQ Revenues Of $26.6M-$27.2M, FY25 Total Revenue Of $739M-$759M

Evercore ISI Group analyst Mark Mahaney upgrades Chewy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) from In-Line to Outperform and raises the price target from $34 to $47.

Upgrades

CHWY

Evercore ISI Group Upgrades Chewy to Outperform, Raises Price Target to $47

The Company intends to use the proceeds from the offering for working capital and general corporate purposes.
The Company intends to use the proceeds from the offering for working capital and general corporate purposes.

VMAR

Vision Marine Technologies Raises $5.8M In Brokered Private Placement

<ul>
<li>Initiated CHAPTER-3, the pivotal Phase 3 study of deucrictibant for prophylaxis against hereditary angioedema (HAE) attacks in 2024; topline data anticipated in 2H2026</li>
<li>Enrollment in RAPIDe-3, the pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, continuing as planned; topline data anticipated in 1Q2026</li>
<li>Study initiation of deucrictibant for the treatment of acquired angioedema due to C1-INH deficiency (AAE-C1INH) anticipated in 2025</li>
</ul>

PHVS

Pharvaris Unveils 2025 Strategic Priorities; Says Operating From Strong Financial Position With Estimated Cash Runway Into 3Q2026

Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is entering a pivotal week, as concerns over a potentially overheating U.S. economy continue to drag down <a href="https://www.benzinga.com/money/bitcoin-price-prediction">the apex cryptocurrency</a>.
What Happened: Following a stronger-than-expected <a href="https://www.benzinga.com/economics/macro-economic-events/25/01/42912480/us-economy-adds-256000-payrolls-in-december-as-tight-labor-market-tops-forecasts-dollar-treasury-yields-spike">non-farm payrolls report</a>, which showed 256,000 jobs added against a forecast of 164,000, fears of accelerated inflation have been reignited, leading to a retreat in equity markets, according to QCP Capital.
The robust employment data has effectively nullified expectations of <a href="https://www.benzinga.com/content/42932732/with-this-kind-of-data-the-fed-isnt-cutting-rates-this-year">near-term interest rate cuts</a> by the Federal Reserve.
Compounding these concerns are the prospects of potential <a href="https://www.benzinga.com/news/global/25/01/42938329/us-reportedly-probes-barriers-subsidies-and-unfair-trade-practices-by-china-in-global-shipbuilding-as-trump-tariff-threat-looms">Trump-era tariffs</a>, which could further escalate inflationary pressures.
Bitcoin is trading around $91,100 in early morning U.S. hours, down 3.4% over the past 24 hours. 
Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) has followed king crypto lower, trading around $3,080, 5.8% down. 
Key economic data releases, including the Producer Price Index (PPI), Consumer Price Index (CPI) and Unemployment Claims are all scheduled for this week. 
Any further signs of an overheating economy could further test the markets, posing a challenge to the narrative that crypto is a safe haven against inflation.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42921493/cryptos-capitol-hill-breakthrough-senate-subcommittee-signals-shifting-political-winds">Crypto&#8217;s Capitol Hill Breakthrough: Senate Subcommittee Signals Shifting Political Winds</a>
Why It Matters: In addition to economic uncertainties, the crypto industry is also seeing significant political developments, President-elect Donald Trump is reportedly forming a cryptocurrency advisory council, comprised of around 24 CEOs and founders, including major figures from industry giants like MicroStrategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), Coinbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) and Circle (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDC</a>), <a href="https://www.bloomberg.com/news/articles/2025-01-09/crypto-ceos-fly-to-mar-a-lago-make-large-donations-as-inauguration-day-nears?embedded-checkout=true">according</a> to Bloomberg.
This council aims to provide guidance on digital asset policy and help draft legislation with Congress. 
The advisors will also work with government agencies, with an aim to establish a <a href="https://www.benzinga.com/25/01/42779917/trump-wont-announce-strategic-bitcoin-reserve-via-executive-order-says-analyst-he-would-likely-buy-btc-in-the-background">strategic Bitcoin reserve</a>.
Crypto.com CEO Kris Marszalek, as well as MicroStrategy executive chairman Michael Saylor, have <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42785039/michael-saylor-meets-eric-trump-says-bitcoin-is-on-the-menu-at-mar-a-lago">visited Mar-a-Lago</a> to discuss policies and potential roles within the incoming administration.
Coinbase CEO Brian Armstrong and Ripple (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) CEO Brad Garlinghouse have also reportedly met with Trump recently to offer their support. 
Circle CEO Jeremy Allaire recently stated that his firm donated 1 million (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDC</a>) to Trump&#8217;s inaugural committee.
The formation of this council, along with the significant involvement of industry leaders, signifies a potential shift toward a more crypto-friendly regulatory environment in the U.S, while simultaneously placing the spotlight on crypto&#8217;s relevance in times of economic uncertainty. 
This week's developments could prove to be a major inflection point for digital assets.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42909925/previewing-todays-most-important-jobs-report-what-it-means-for-bitcoin">Previewing Today&#8217;s &#8216;Most Important Jobs Report&#8217; — What It Means For Bitcoin</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

$USDC

$XRP

COIN

MSTR

Bitcoin Slides To $91,000 Ahead Of Upcoming Key Inflation Data

Wallbox Receives U.S. UL Certification For Quasar 2 Bidirectional Charger

Evercore ISI Group analyst David Raso upgrades Caterpillar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) from Underperform to In-Line and announces $365 price target.

Evercore ISI Group Upgrades Caterpillar to In-Line, Announces $365 Price Target

The Company will report fourth quarter and fiscal year 2024 financial results on February 25, 2025, and will provide detailed results and 2025 guidance at that time.
The Company also expects full year 2024 adjusted operating margin to be at the high end of the previous guidance range of 10.5–11.0%.&nbsp;
In addition, Amer Sports announced that it has repaid all $1.2 billion of its outstanding term loans in the fourth quarter and expects fiscal year 2025 adjusted net finance costs to approximate $120 million, as compared to the previous guidance of $180-190 million.

Amer Sports Expects FY24 Revenue Growth To Be At High End Of Prior Guidance Range Of 16 – 17% Despite Currency Headwinds In Q4

Biotech

MDGL

Madrigal Pharmaceuticals Reports Preliminary Q4 And FY2024 Rezdiffra (Resmetirom) Net Sales Of $100M-$103M And $177M-$180M, Respectively, With Preliminary Cash Balance Of Approximately $931M, And As Of Year-end 2024, More Than 11,800 Patients On Rezdiffra

On a Preliminary Basis, for the Fourth Quarter (13-weeks ended December 31, 2024), the Company expects:
<ul>
<li>Total revenues in the range of $211 million to $216 million, an increase from its previous guidance of $210 million to $215 million and representing growth of 10% at the mid-point of the range from fourth quarter fiscal 2023 total revenues of $194.8 million; and</li>
<li>Adjusted EBITDA in the range of $25.5 million to $27.5 million, an increase from its previous guidance of $25 million to $27 million and representing growth of 13% at the mid-point of the range from fourth quarter fiscal 2023 adjusted EBITDA of $23.4 million.</li>
</ul>
On a Preliminary Basis, for the Fiscal Year 2024 (52-weeks ended December 31, 2024), the Company expects:
<ul>
<li>Total revenues in the range of $889 million to $894 million, an increase from its previous guidance of $888 million to $893 million and representing growth of 12% at the mid-point of the range from total revenues of $794 million in fiscal year 2023; and</li>
<li>Adjusted EBITDA in the range of $110.5 million to $112.5 million, an increase from its previous guidance of $110 million to $112 million and representing growth of 25% at the mid-point of the range from Adjusted EBITDA of $89.2 million in fiscal year 2023.</li>
</ul>
The Company is introducing Fiscal Year 2025 Guidance (52-weeks ending December 31, 2025) and expects:
<ul>
<li>Total revenues in the range of $950 million to $970 million; and</li>
<li>Adjusted EBITDA in the range of $115 million to $125 million.</li>
</ul>

OneSpaWorld Expects Q4 Revenue Of $211M-$216M (Prior $210M-$215M) Vs $213.9M Est, FY24 Revenue Of $889M-$894M (Prior $888M-$893M) Vs $891.7M Est, FY25 Revenue Of $950M-$970M Vs $968.97M Est

<ul>
<li>Strategy prioritizes most accelerated path to first potential approval&nbsp;</li>
<li>Initial NDA submission expected by mid-year for zidesamtinib in TKI pre-treated ROS1-positive NSCLC population, with topline pivotal data anticipated in the first half of 2025</li>
<li>Topline pivotal data for neladalkib (NVL-655) in TKI pre-treated ALK-positive NSCLC population anticipated by year-end 2025</li>
</ul>

NUVL

Nuvalent Targets 2026 Approval With Accelerated NDA For Zidesamtinib In ROS1-Positive NSCLC

USFD

US Foods Holding Reaffirms Previously Announced FY24 Guidance For Net Sales Of $37.7B - $38.0B  (Est $37.878B), Adjusted EPS Of $3.05 - $3.15 (Est $3.12)

a.k.a. Brands Announces New Leadership: Ciaran Long As CEO, Kevin Grant As CFO

AIRS

AirSculpt Technologies Expects 2024 Revenues Of Approximately $180M Compared To Previous Guidance Of $183M-$189M And Consensus Of $185.601M, With Adjusted EBITDA Of ~$20.5M Compared To Prior Guidance Of $23M-$28M

The most oversold stocks in the real estate sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the<a href="https://www.benzinga.com/topic/rsi"> RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Forestar Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOR#NYSE">FOR</a>)</h3>
<ul>
<li>On Jan. 6, Citigroup analyst Anthony Pettinari maintained Forestar Group with a Buy and lowered the price target from $43 to $39. The company' stock fell around 10% over the past month and has a <a href="https://www.benzinga.com/quote/FOR">52-week low of $24.81</a>.</li>
<li>RSI Value: 20.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>FOR Price Action: Shares of Forestar Group fell 2.5% to close at $25.10 on Friday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011325&amp;t=be2bearmibe3na1">latest FOR news</a>.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011325&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="901" height="852" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13064401/image-69.png" alt="" class="wp-image-730282" style="width:649px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13064401/image-69.png 901w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13064401/image-69-300x284.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13064401/image-69-768x726.png 768w" sizes="(max-width: 901px) 100vw, 901px" /></a></figure>
<h3 class="wp-block-heading">American Assets Trust, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAT#NYSE">AAT</a>)</h3>
<ul>
<li>American Assets Trust will announce its fourth quarter and year-end 2024 earnings after the market closes on Tuesday, Feb. 4. The company's stock fell around 10% over the past five days and <a href="https://www.benzinga.com/quote/AAT">has a 52-week low</a> of $20.03.</li>
<li>RSI Value: 22.7</li>
<li>AAT Price Action: Shares of American Assets Trust fell 3.2% to close at $23.56 on Friday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011325&amp;t=be2bearmibe3na1">trend in AAT stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011325&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="907" height="833" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13064428/image-70.png" alt="" class="wp-image-730284" style="width:536px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13064428/image-70.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13064428/image-70-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13064428/image-70-768x705.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
<h3 class="wp-block-heading">Alexander&#8217;s Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALX#NYSE">ALX</a>)</h3>
<ul>
<li>On Nov. 4, Alexander&#8217;s posted better-than-expected quarterly results. The company's stock fell around 12% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/ALX">low of $185.00.</a></li>
<li>RSI Value: 25.9</li>
<li>ALX Price Action: Shares of Alexander&#8217;s fell 6.6% to close at $186.88 on Friday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011325&amp;t=be2bearmibe3na1">breakout in ALX shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011325&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="880" height="836" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13064521/image-71.png" alt="" class="wp-image-730285" style="width:552px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13064521/image-71.png 880w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13064521/image-71-300x285.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13064521/image-71-768x730.png 768w" sizes="(max-width: 880px) 100vw, 880px" /></a></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42923396/wall-streets-most-accurate-analysts-weigh-in-on-3-real-estate-stocks-with-over-7-dividend-yields-2">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Real Estate Stocks With Over 7% Dividend Yields</a></li>
</ul>

Long Ideas

Pre-Market Outlook

Markets

Trading Ideas

Top 3 Real Estate Stocks That May Rocket Higher This Quarter

B of A Securities analyst Chase Mulvehill downgrades Atlas Energy Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AESI#NYSE">AESI</a>) from Buy to Neutral and maintains the price target from $22.5 to $22.5.

Downgrades

AESI

B of A Securities Downgrades Atlas Energy Solutions to Neutral, Maintains Price Target to $22.5

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Arcutis Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQT#NASDAQ">ARQT</a>) with a Buy and maintains $19 price target.

ARQT

HC Wainwright & Co. Reiterates Buy on Arcutis Biotherapeutics, Maintains $19 Price Target

VIG: I'm Downgrading This $93 Billion Dividend Growth ETF

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Betting on the best ETFs to buy now can help simplify your investment strategy.



ETFs, or exchange-traded funds, are a compelling way for investors to beat the market without having to manage a boatload of individual stocks. Moreover, these funds tend to offer exposure to multi-year trends and themes, making them ideal bets for diversifying investment portfolios.



As we advance, ETFs will continue gaining popularity, with their appeal largely tied to their low-maintenance nature, minimal fees, and the ability to target a swath of stocks with a single investment.



That said, here are the three best ETFs to buy, effectively aligning with a strategic, low-cost investment approach. These top ETFs have been excellent performers over the years, with robust fundamentals while offering healthy long-term upside potential. Moreover, they have had an excellent track record of offering steady returns for their investors, which adds to their attractiveness.



<h2>Best ETFs to Buy: iShares US Technology ETF (IYW)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/02/ishares1600-300x169.jpg" alt="iShares by Blackrock sign"><div>Source: Sundry Photography / Shutterstock.com</div></div>Investing in the iShares US Technology ETF&nbsp;(NYSEARCA:<a href="https://investorplace.com/stock-quotes/iyw-stock-quote/">IYW</a>) feels like a tech enthusiast&rsquo;s dream come true. IYW stock offers access to some of the elite U.S. tech companies, including heavyweights that have led the market to monumental gains. Roughly 45% of its total assets are made up of three of the biggest <a href="https://investorplace.com/industries/technology/">tech stocks</a> in Microsoft (NASDAQ:<a href="https://investorplace.com/stock-quotes/msft-stock-quote/">MSFT</a>), Apple (NASDAQ:<a href="https://investorplace.com/stock-quotes/aapl-stock-quote/">AAPL</a>), and Nvidia (NASDAQ:<a href="https://investorplace.com/stock-quotes/nvda-stock-quote/">NVDA</a>). With these elite U.S. tech companies leading the charge, IYW stock is positioned enviably to outperform the broader market with considerable aplomb.



Moreover, IYW&rsquo;s appeal is bolstered further by its <a href="https://seekingalpha.com/symbol/IYW/expenses">reasonable 0.40% expense ratio</a>, making it a cost-effective option for tech investors. Also, IYW stock has trumped broader market gains and then some over the past decade. Its 10-year return stands at 531%, which comfortably beats the S&amp;P 500&rsquo;s 179% gain. This discrepancy can be seen across multiple time horizons, including last year where <a href="https://seekingalpha.com/symbol/IYW/momentum/performance">IYW stock was up 43%</a> while the broader market was up 24%.



<h2>Global X Artificial Intelligence &amp; Technology ETF (AIQ)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/04/ai-stocks1600-7-300x169.png" alt="AI Artificial Intelligence. Businessman using AI technology for data analysis, coding computer language with digital brain, machine learning on virtual screen, business intelligence. AI stocks"><div>Source: Tapati Rinchumrus / Shutterstock.com</div></div>AI has been hands-down the biggest investing trend in the past year, and perhaps the Global X Artificial Intelligence &amp; Technology ETF (NASDAQ:<a href="https://investorplace.com/stock-quotes/aiq-stock-quote/">AIQ</a>) offers investors a front-row seat to the industry&rsquo;s finest. With a robust annual growth of 31% in the past year <a href="https://seekingalpha.com/symbol/AIQ/momentum/performance">and over 120% in the past five years</a>, AIQ stands out as a top performer among AI-focused ETFs. Its portfolio of 91 holdings and <a href="https://seekingalpha.com/symbol/AIQ/expenses">a competitive 0.68% total expense ratio </a>make it an attractive option for those looking to pounce on the burgeoning AI and big data sectors.



Moreover, with its top 10 holdings representing 36% of total assets, AIQ stock effectively mitigates risk better than most of its peers. Nvidia plays a key role in driving its stock, but its investments across the AI landscape effectively shield it from downside risk. This strategic distribution ensures that the remaining portfolio components can sustain the fund&rsquo;s performance when Nvidia is in correction territory.



<h2>Avantis U.S. Large Cap Value ETF (AVLV)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/etf-1600-2-300x169.png" alt="Blocks that spell out ETF in front of jar with money and change."><div>Source: SHUN_J / Shutterstock</div></div>The Avantis U.S. Large Cap Value ETF (NYSEARCA:<a href="https://investorplace.com/stock-quotes/avlv-stock-quote/">AVLV</a>) offers investors an excellent opportunity to tap into high-quality, bargain large-cap U.S. stocks. By focusing on stocks trading at lower valuations and strong profit margins, the Avantis ETF aims to significantly enhance potential returns.



The ETF currently manages over $3.6 billion in assets, spanning various sectors, including healthcare, technology, financial services, etc. Moreover, <a href="https://seekingalpha.com/symbol/AVLV/holdings" target="_blank">it has holdings in 314 companies</a>, with investments in some of the stock market&rsquo;s darlings, including Meta (NASDAQ:<a href="https://investorplace.com/stock-quotes/meta-stock-quote/">META</a>),&nbsp;JPMorgan Chase&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/jpm-stock-quote/">JPM</a>), Costco&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/cost-stock-quote/">COST</a>)&nbsp;



The fund&rsquo;s balanced approach, targeting undervalued profitable companies, gives it an edge. It effectively provides an investment vehicle for diversifying their portfolio with strong, stable, and growth-oriented assets. Moreover, <a href="https://seekingalpha.com/symbol/AVLV/dividends/scorecard" target="_blank">AVLV stock yields 1.62%</a>, with two consecutive years of payout growth. Though its payout growth rate may be unimpressive, I wouldn&rsquo;t want bet against the massive potential of large-cap U.S. stocks.



On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines



On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.
<div>Muslim Farooque is a keen investor and an optimist at heart. A life-long gamer and tech enthusiast, he has a particular affinity for analyzing technology stocks. Muslim holds a bachelor&rsquo;s of science degree in applied accounting from Oxford Brookes University.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/07/the-3-best-etfs-to-buy-in-july-2024/">The 3 Best ETFs to Buy in July 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

The 3 Best ETFs to Buy in July 2024

AVLV: An Active Value Approach That Works

Avantis U.S. Large Cap Value ETF declares quarterly distribution of $0.2731

AVLV: Low Valuations, Risk-Reward Not As Attractive Due To Sector Exposure

SPVU: Improved Outlook But This Enhanced Value ETF Isn't The Best Choice

COWZ: Q4 2024 Reconstitution Sets The Stage For A Showdown With VFLO In 2025

AVLV: Competes Well With VTV, And May Benefit From Other Tailwinds

VLU: A Quiet Performer With Solid Value Features

Value 10 screen from BofA as January 2025 equity trading launches

AAPL

ACGL

AVLV

CGDV

COST

COWS

COWZ

DGRW

FDVV

FELV

FLOW

MSFT

NVDA

PVAL

SCHD

SPTM

SPVU

SPYV

STLD

VFLO

Comments

Avantis U.S. Large Cap Value ETF

News

Latest news for Avantis U.S. Large Cap Value ETF (ARCA:AVLV)

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga